Stopping abnormal androgen production in CHD1‑deficient prostate cancer
Mechanism and therapeutic targeting of abnormal androgenesis in CHD1-deficient prostate cancer
Researchers aim to develop ways to block abnormal hormone production that helps prostate tumors grow in men whose cancers lack the CHD1 gene.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project ID | NIH-11311329 on NIH RePORTER |
What this research studies
As a patient, you'll hear that the team is studying why some prostate cancers make their own androgens and resist hormonal drugs. They will examine tumor tissue, lab-grown cancer cells, and animal models to see how loss of the CHD1 gene turns on steroid-making genes inside tumors. The researchers will test drugs and strategies to shut down intratumoral androgen synthesis and to restore sensitivity to existing anti-androgen therapies. Much of the work is preclinical but may involve donating tumor samples or clinical data to guide treatments toward early human testing.
Who could benefit from this research
Good fit: Men with advanced or recurrent prostate cancer, especially those whose tumors have CHD1 deletions or who have progressed on AR-directed therapies, would be the most relevant candidates.
Not a fit: Men with early-stage disease or tumors that do not rely on intratumoral androgen synthesis (no CHD1 loss) are less likely to benefit from this work.
Why it matters
Potential benefit: If successful, this work could lead to new treatments that stop tumors from making their own androgens and improve responses to hormonal therapies.
How similar studies have performed: Drugs that block androgen production (for example, abiraterone) help many men but resistance commonly develops, and targeting CHD1-related mechanisms is a newer preclinical approach with limited clinical data so far.
Where this research is happening
Rochester, United States
- Mayo Clinic Rochester — Rochester, United States (Active)
Researchers
- Principal investigator: Domingo-Domenech, Josep Maria — Mayo Clinic Rochester
- Study coordinator: Domingo-Domenech, Josep Maria
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.